Finishing school for biotechnologists inaugurated
Federation of Asian Biotech Associations (FABA), Indian Immunologicals Limited (IIL), and Agri Biotech Foundation (ABF) have officially inaugurated their collaborative finishing school programme at the Agri Biotech Foundation, Rajendra Nagar, here on Wednesday.
FABA executive president and ABF vice president Prof. Reddanna said the one-month course is meant to bridge the industry-academia gap in biotechnology with extensive hands-on training in state-of-the-art wet lab facilities.
IIL managing director Anand Kumar traced the growth of the institute in becoming the world's largest vaccine maker, producing human vaccines as well, including Rabies and Hepatitis A vaccines.
Director of AGF Pakki Reddy said the organisation had taken up over 100 projects in collaboration with many institutions and had established centres in Mahbubnagar and Nalgonda, working with castor, groundnut, and pigeon pea crops, as well as in the animal sector, said a press release.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
30-05-2025
- Time of India
Uno Minda introduces UnoMindaKart: A platform for online access to automotive solutions
Uno Minda , a major automotive supplier in India, has launched UnoMindaKart , a direct-to-consumer platform, to provide customers with easy access to auto components. This initiative marks Uno Minda as the first aftermarket brand in India to offer products online through its own platform, aiming to transform the way customers purchase automotive parts. The platform offers over 5,000 SKUs across 30 categories, including spare parts and car accessories, and incorporates tools like the 'Add My Vehicle' feature and a 3D Visualizer to enhance the customer experience. Uno Minda's new D2C platform, UnoMindaKart, is designed to revolutionize how customers in the Indian aftermarket access automotive components. The platform offers a wide array of products for various automotive segments, including two-wheelers, three-wheelers, cars, commercial vehicles, tractors, and off-road vehicles. The website boasts a comprehensive selection of over 5,000 SKUs, categorized into more than 30 segments. These include over 24 categories of spare parts and 10 categories of car accessories, catering to diverse automotive needs. Anand Kumar , Head of Strategy & Product, Uno Minda Aftermarket , said "We are thrilled to introduce our new D2C platform, which embodies our commitment to innovation and customer satisfaction. UnoMindaKart offers automotive solutions for all major segments in the Indian automotive industry, i.e., 2W, 3W, Car, Commercial, tractor & Offroad." Features -A key feature of the UnoMindaKart website is the 'Add My Vehicle' tool. This feature allows customers to input their vehicle details and receive personalized product recommendations, ensuring a precise fit. -The platform also includes a 3D Visualizer, providing an augmented reality experience. This allows users to see Uno Minda components in their actual fitment locations. -Additionally, the Wheelz Visualizer enables customers to virtually explore and test various Uno Minda alloy wheels. This feature allows them to see how different styles would look on their vehicles before making a purchase. -To further assist customers, Uno Minda has integrated a web bot. This acts as a personal assistant to help in buying decisions and ensure customer satisfaction. Customers can now purchase Uno Minda products directly from the website. The website address is .
Economic Times
27-05-2025
- Economic Times
We can VAXit Bharat: Public sector alone can't make India biotech-ready; firms, startups must jump in
(Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of .) Covid cases are on the rise again. But not at any alarming rate. Further, the strains that are spreading now cause relatively mild symptoms, and hospitals are equipped to handle Covid patients, armed as they are with experience, hindsight and, one hopes, enough is India prepared for the attack of some new virus? Can we rapidly develop an effective vaccine, test it, and scale up production to cover our population? Not really, if we go by the cavalier disregard with which GoI treated our scientists' spectacular success in developing an indigenous vaccine for lumpy skin disease in cattle, which has spread to India from its original home in Africa, and killed some 97,000 heads of cattle in a 2022 outbreak, and decreased milk production by 25% in the affected come in different types. For smallpox, a weakened but live virus - live attenuated virus - was used as the vaccine. Inactivated vaccines use the dead virus to generate an immune response, as with hepatitis A and RNA (mRNA) vaccines instruct the host's body to generate the virus protein, so that the immune system would start producing antibodies against the alien presence. This was famously used to combat Covid, with Moderna - which had received a grant of $25 mn in 2013 from the US Defense Advanced Research Projects Agency (Darpa) to develop mRNA therapeutics - developing an effective Covid vaccine, and claiming that the other developer of an mRNA vaccine, Pfizer-BioNTech, had stolen its vaccines code for the antigen itself. Once introduced into the host's body, they induce the host to produce the antigen, which, then, stimulates an immune response. Sub-unit, recombinant, polysaccharide and conjugate vaccines use bits and pieces of the virus, like its protein, sugar or the casing around it, to stimulate an immune response. An example is Novavax, an American Covid vaccine that genetically engineered nanoparticles of the coronavirus' spike protein, which, when inside the host body, produce an immune response. The vaccine against cervical cancer falls in this category.A viral vector vaccine strips a virus like adenovirus (common cold) of its disease-generation capacity, and encodes in its genes instructions to manufacture the antigen of the pathogen against which the vaccine seeks to protect the host. AstraZeneca or Covishield vaccine is of this type. Then there are toxoid vaccines, such as anti-tetanus, in which some bit of the toxin is introduced in the body, to stimulate the needed immune vaccines, mRNA vaccines and recombinant viral vector vaccines offer standardised platforms, in which you alter coding instructions to produce the protein of your choice to produce the desired immune from the all-important immunity-generating content, vaccines also have pure water, stabilisers, adjuvants, antibiotics, etc. These also call for R&D. Vaccine administration is another area of research. There are several possibilities - oral, injection, skin patch. Making vaccines stay stable in room temperature would be ideal. But at least at fridge temperature is vital. mRNA vaccine originally called for storage at ultra-low temperatures, but research raised the storage temperature to normal refrigerator temperature. Operation Sindoor has given high visibility to ordnance that flies. But not all wars will be fought with weapons that create pyrotechnics. Cyberattacks are a vital area of concern. So is biological warfare. A chain is as strong as its weakest link. National security calls for strength in all sectors of potential to prepare for a fresh pandemic or to strengthen our defences in the eventuality of germ warfare, India needs new energy in its biotech research. Does India have the capacity to carry out such research? It absolutely lumpy skin disease vaccine was developed by collaboration among different facilities of Indian Council of Agricultural Research (ICAR), such as National Research Centre on Equines (NRCE) and National Centre for Veterinary Type Cultures (NCVTC) at Hisar, Haryana. NRCE's Naveen Kumar, after a 2019 outbreak of lumpy skin disease, set out to isolate the virus strain, and with the full backing of his boss, B N Tripathi, he proceeded to develop an attenuated live virus Veterinary Research Institute (IVRI), Bareilly, UP, and National Institute of High Security Animal Diseases (NIHSAD), Bhopal, MP, were roped in. Working through Covid's lost years, when much of the country stood still, these scientists developed an effective vaccine, which could, in addition, help distinguish between vaccinated and unvaccinated vaccine was ready in 2022. Its formal approval took 2½ years. It was licensed to an arm of Bharat Biotech. Yet, no central minister was available to release the vaccine and celebrate this rare achievement of Indian scientists. The vaccine was released by Andhra Pradesh CM N Chandrababu Naidu at a livestock summit in Vijayawada, earlier this sector research needs to be recognised and celebrated. But the public sector alone cannot make India biotech-ready. For that, existing biotech companies and new startups must abandon their risk aversion, and plunge into R& with defence startups, the risk capital must come from both government and modest slices of our large retirement savings. Alongside mutual funds, venture funds that feed into national security must be considered 'sahi hai'.
Time of India
09-05-2025
- Time of India
ICAI postpones May 2025 CA exams amid security concerns
Pune: The Institute of Chartered Accountants of India (ICAI) decided to postpone the remaining papers of the earlier scheduled for May 2025, considering the security concerns in the remaining papers of the CA Final, Intermediate and Post-Qualification Course (International Taxation Assessment Test - INTT AT) scheduled from May 9 to May 14, 2025, were secretary (examinations) Anand Kumar stated in a statement issued by ICAI, "In partial modification of the 'Institute's Important Announcement' dated Jan 13, 2025, it is announced that in view of the tense and security situation in the country, the remaining papers of Chartered Accountants, May 9, 2025, to May 14, 2025, stand postponed. Tired of too many ads? go ad free now The revised dates will be announced in due course."Candidates registered for the CA exam can visit the ICAI website to check the official notification. According to the previous schedule, the ICAI CA May 2025 exam dates were planned between May 2 and May 14. In the CA Intermediate exam, Group 1 papers were to be held on May 3, 5, and 7, while Group 2 exams were scheduled for May 9, 11, and 14. Similarly, in the CA Final exam, Group 1 papers were to be conducted on May 2, 4, and 6, and Group 2 papers on May 8, 10, and 13, intermediate exams were to take place daily from 2pm to 5pm. For the final course exams, the timing for papers 1 to 5 was from 2pm to 5pm, while paper 6 was scheduled from 2pm to 6pm. Pune: The Institute of Chartered Accountants of India (ICAI) decided to postpone the remaining papers of the chartered accountancy exams earlier scheduled for May 2025, considering the security concerns in the remaining papers of the CA Final, Intermediate and Post-Qualification Course (International Taxation Assessment Test - INTT AT) scheduled from May 9 to May 14, 2025, were secretary (examinations) Anand Kumar stated in a statement issued by ICAI, "In partial modification of the 'Institute's Important Announcement' dated Jan 13, 2025, it is announced that in view of the tense and security situation in the country, the remaining papers of Chartered Accountants, May 9, 2025, to May 14, 2025, stand postponed. The revised dates will be announced in due course."Candidates registered for the CA exam can visit the ICAI website to check the official notification. According to the previous schedule, the ICAI CA May 2025 exam dates were planned between May 2 and May 14. In the CA Intermediate exam, Group 1 papers were to be held on May 3, 5, and 7, while Group 2 exams were scheduled for May 9, 11, and 14. Similarly, in the CA Final exam, Group 1 papers were to be conducted on May 2, 4, and 6, and Group 2 papers on May 8, 10, and 13, intermediate exams were to take place daily from 2pm to 5pm. For the final course exams, the timing for papers 1 to 5 was from 2pm to 5pm, while paper 6 was scheduled from 2pm to 6pm.
